• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Rebiotix Begins Clinical Trial of Therapy for the Treatment of RecurrentClostridium difficile-Associated Diarrhea

Download this press release (449 KB).

ROSEVILLE, Minn. (June 24, 2013) — Rebiotix Inc. has announced that physicians have treated the first patients as part of the PUNCH™ CD Phase 2 clinical trial of RBX2660 (microbiota suspension) for the treatment of recurrent Clostridium difficile-associated diarrhea (CDAD). RBX2660 represents the first drug product in the Rebiotix Microbiota Restoration Therapy (MRT) platform.

The purpose of the PUNCH CD study is to assess the safety of RBX2660, a drug preparation containing live human derived microbes. Secondary objectives of the multi-center, open-label study include gathering information on the efficacy and cost-effectiveness of the therapy. Approximately 40 patients at up to 20 centers in the US and Canada will take part in the study. Patients will be followed for six months after treatment.

First use of RBX2660, a unique, non-antibiotic drug treatment for recurrent CDAD, took place at the Metropolitan Gastroenterology Group, Chevy Chase, Md. “We are pleased that we have initiated the PUNCH CD study on schedule,” said Rebiotix CEO Lee Jones. “RBX2660 has the potential to reduce dependence on antibiotics which have been shown to have limited effectiveness in treating multiply recurrent CDAD.”

The US Food and Drug Administration recognized the urgent need for a new therapy for recurrent Clostridium difficile infection (CDI) and granted Fast Track status to the RBX2660 clinical program earlier this summer. The Fast Track designation is meant to facilitate the development and expedite the review of new drugs or biologic products that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Rebiotix received Investigational New Drug approval from the FDA in July.

About Clostridium difficile Infection

CDI is a life-threatening intestinal infection that is usually hospital-acquired. It affects more than 700,000 people in the US annually, placing an estimated $3 billion burden the healthcare system. Symptoms of CDI include profuse watery diarrhea and abdominal pain. In healthy individuals, a mix of “good” and “bad” gut microbes work together to regulate human functions. In patients with CDI, the disease-causing bacteria predominate.

About Microbiota Restoration Therapy

MRT is patterned after fecal transplants, a technique that has demonstrated success in the treatment of serious gastrointestinal illnesses, including CDI, for more than 50 years. Fecal transplant therapy has failed to be widely adopted due to challenges involved in donor screening and product preparation. MRT solves these problems by making available a standardized product in a ready-to-use format. RBX2660 has the potential to treat disease by overwhelming the disease-causing bacteria and restoring a patient’s healthy gut microbial community.

Rebiotix Development Program

Rebiotix Inc. is aggressively pursuing a solution to the critical health concerns posed by CDI and has gone from concept to clinical application in less than two years. This pioneering effort is based on new knowledge about the human microbiome showing the importance of microbes that live inside the human body in the genesis and modulation of human disease.

The company believes that MRT has great potential benefits for the treatment of other GI disease, such as ulcerative colitis, and is actively pursuing a research program to develop additional MRT products.


About Rebiotix

Rebiotix Inc. is a results-oriented biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome. The Roseville, Minn.-based company is pioneering Microbiota Restoration Therapy to reverse pathogenic processes and restore healthy gut flora through the transplantation of live microorganisms. For more information, visit www.Rebiotix.com.

Press Releases Press Releases

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT